<SEC-DOCUMENT>0001125345-24-000123.txt : 20240523
<SEC-HEADER>0001125345-24-000123.hdr.sgml : 20240523
<ACCEPTANCE-DATETIME>20240523162227
ACCESSION NUMBER:		0001125345-24-000123
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20240523
DATE AS OF CHANGE:		20240523
EFFECTIVENESS DATE:		20240523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279674
		FILM NUMBER:		24978604

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>form_s-8x2024eip.htm
<DESCRIPTION>S-8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie62da5e3a6b84808a0dfc40400a06642_1"></div><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As filed with the Securities and Exchange Commission on May 23, 2024 </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registration No. 333- </font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM S-8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">REGISTRATION STATEMENT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">UNDER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">THE SECURITIES ACT OF 1933 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.303%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">06-1591613</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. employer</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">identification no.)</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9704 Medical Center Drive, Rockville, MD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20850</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip code)</font></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Equity Incentive Plan, As Amended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Full title of plan) </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Scott Koenig, M.D., Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9704 Medical Center Drive</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rockville, MD 20850 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(301) 251-5172</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Name, address, including zip code, and telephone number, including area code, of agent for service) </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Copies to&#58; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jeffrey Peters</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Vice President and General Counsel</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9704 Medical Center Drive</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rockville, MD 20850</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(301) 251-5172</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eric Blanchard</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Madison Jones</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reid Hooper</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cooley LLP</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">500 Boylston Street, 14th Floor<br>Boston, Massachusetts 02116</font></div><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(617) 937-2300</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"><tr><td style="width:1.0%"></td><td style="width:28.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.105%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPLANATORY NOTE </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This registration statement on Form S-8 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is being filed for the purpose of registering 2,000,000 shares of common stock of MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) issuable pursuant to the MacroGenics, Inc. 2023 Equity Incentive Plan, As Amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 EIP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The contents of the Registrant&#8217;s registration statement on Form S-8 related to the 2023 EIP, filed with the Securities and Exchange Commission on June 6, 2023 (File No. 333-272451), are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8. The additional 2,000,000 shares of common stock registered pursuant to this Registration Statement were authorized pursuant to an amendment to the 2023 EIP that was approved by the Registrant&#8217;s stockholders at the Registrant&#8217;s annual meeting of stockholders held on May 21, 2024.</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION REQUIRED IN REGISTRATION STATEMENT </font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incorporation of Documents by Reference. </font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and in accordance therewith files reports and other information with the Commission. The following documents, which are on file with the Commission, are incorporated in this Registration Statement by reference&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on March 7, 2024&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Registrant&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, filed with the Commission on May 9, 2024&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Registrant&#8217;s Current Reports on Form 8-K (except for the information furnished under Item 7.01 therein) filed with the Commission on April 3, 2024, May 9, 2024 (Item 8.01) and May 23, 2024&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Registrant&#8217;s Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 8, 2024, but only to the extent such information is incorporated by reference in the Registrant&#8217;s Annual Report on&#160;Form 10-K&#160;for the fiscal year ended December 31, 2023&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The description of the Registrant&#8217;s common stock contained in Exhibit 4.2 to its Annual Report on Form 10-K filed with the SEC on February 25, 2021, including any amendments or reports filed for the purpose of updating such description.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All reports and definitive proxy or information statements filed pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such statements as set forth therein. Unless expressly incorporated into this Registration Statement, a report furnished on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.<br></font></div><div style="margin-top:6pt"><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 8.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:8.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.521%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br>No.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Exhibit</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="consentofcooleyexhibit51.htm" style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">5.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="consentofcooleyexhibit51.htm" style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Opinion of Cooley LLP</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="consentofernstyoungllpex231.htm" style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">23.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="consentofernstyoungllpex231.htm" style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consent of Ernst &#38; Young LLP</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="consentofcooleyexhibit51.htm" style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">23.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="consentofcooleyexhibit51.htm" style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consent of Cooley LLP (included in Exhibit 5.1)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ie62da5e3a6b84808a0dfc40400a06642_65" style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">24.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ie62da5e3a6b84808a0dfc40400a06642_65" style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Powers of Attorney (included on signature page). </a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000076/0001125345-24-000076-index.htm" style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">99.1</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000076/0001125345-24-000076-index.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MacroGenics, Inc. 2023 Equity Incentive Plan, </a><a href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000076/0001125345-24-000076-index.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">A</a><a href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000076/0001125345-24-000076-index.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">s </a><a href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000076/0001125345-24-000076-index.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">A</a><a href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000076/0001125345-24-000076-index.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">mended (incorporated by reference to Appendix A to the Definitive Proxy Statement on Schedule 14A, filed on April 8, 2024)</a><a href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000076/0001125345-24-000076-index.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">.</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="filingfeetableexhibit107.htm" style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">107</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="filingfeetableexhibit107.htm" style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Filing Fee Table</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Filed herewith.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undertakings. </font></td></tr></table></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rule 415 offering.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant hereby undertakes&#58;</font></div><div style="margin-top:6pt;padding-left:41.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement&#58;</font></div><div style="margin-top:6pt;padding-left:83.1pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933&#59;</font></div><div style="margin-top:6pt;padding-left:83.1pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement&#59; and</font></div><div style="margin-top:6pt;padding-left:83.1pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement&#59;</font></div><div style="margin-top:6pt;padding-left:41.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that&#58;</font></div><div style="margin-top:6pt;padding-left:41.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paragraphs (a)(1)(i)&#160;and (a)(1)(ii)&#160;do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement&#59; and</font></div><div style="margin-top:6pt;padding-left:41.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">bona fide</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;offering thereof.</font></div><div style="margin-top:6pt;padding-left:41.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of its annual report pursuant to Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934 that is incorporated by reference in the registration statement shall be deemed to be a new registration statement </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">bona fide</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;offering thereof.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</font></div><div><font><br></font></div><div id="ie62da5e3a6b84808a0dfc40400a06642_65"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, the undersigned directors and officers of MacroGenics, Inc., a Delaware corporation, do hereby constitute and appoint Scott Koenig, M.D., Ph.D., Chief Executive Officer and James Karrels, Chief Financial Officer, and each and any of them, our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, to do any and all acts and things in our names and on our behalf in our capacities as directors and officers and to execute any and all instruments for us and in our name in the capacities indicated below, which said attorneys and agents may deem necessary or advisable to enable said corporation to comply with the Securities Act and any rules, regulations and requirements of the SEC, in connection with this registration statement, or any registration statement for this offering under the Securities Act, including specifically, but without limitation, any and all amendments (including post-effective amendments) hereto&#59; and we hereby ratify and confirm all that said attorneys and agents, or either of them, shall do or cause to be done by virtue thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following perso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ns on May 23, 2024.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURE&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TITLE&#58;</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott Koenig, M.D., Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Karrels</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Financial Officer and Secretary<br>(Principal Financial Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lynn Cilinski</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President, Controller and Treasurer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Accounting Officer)</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lynn Cilinski</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William Heiden</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Heiden</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Karen Ferrante, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Ferrante, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Edward Hurwitz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edward Hurwitz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott Jackson</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Jackson</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Meenu Chhabra Karson</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meenu Chhabra Karson</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Margaret A. Liu, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margaret A. Liu, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Federica O&#8217;Brien</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federica O&#8217;Brien</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jay Siegel, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay Siegel, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Stump, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Stump. M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>consentofcooleyexhibit51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib56e82552c0149d0909d2e297b647d21_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Exhibit 5.1</font></div><div><font><br></font></div><div><font><br></font></div></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:136px"></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Eric Blanchard</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:139%">+1 212 479 6565</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:139%">eblanchard&#64;cooley.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">May 23, 2024 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">MacroGenics, Inc. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">9704 Medical Center Drive</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Rockville, MD 20850</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We have acted as counsel to MacroGenics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), in connection with the filing by the Company of a Registration Statement on Form S-8 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Registration Statement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Commission</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) covering the offering of up to 2,000,000 shares (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) of the Company&#8217;s common stock, par value $0.01 per share, pursuant to the Company&#8217;s 2023 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectus, (b) the Company&#8217;s certificate of incorporation and bylaws, each as currently in effect, (c) the Plan and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and related prospectus, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof and we have no obligation or responsibility to update </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:10.00pt">COOLEY LLP 500 BOYLSTON STREET 14TH FLOOR BOSTON, MASSACHUSETTS  02116</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:10.00pt">PHONE&#58;  (617) 937-2300 FAX&#58;  (617) 937-2400 COOLEY.COM</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Exhibit 5.1</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Sincerely,</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cooley LLP</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.666%"><tr><td style="width:1.0%"></td><td style="width:13.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Blanchard </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Blanchard</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:10.00pt">COOLEY LLP 500 BOYLSTON STREET 14TH FLOOR BOSTON, MASSACHUSETTS  02116</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:10.00pt">PHONE&#58;  (617) 937-2300 FAX&#58;  (617) 937-2400 COOLEY.COM</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>consentofernstyoungllpex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic7f3658e781b40b084ef4a623641ffb6_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="padding-left:252pt;text-align:right;text-indent:157.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We consent to the incorporation by reference in the Registration Statement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Form S-8), filed on May 23, 2024, </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">pertaining to the 2023 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Equity Incentive Plan </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MacroGenics, Inc. </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">of our reports dated March 7, 2024, with respect to the consolidated financial statements of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MacroGenics, Inc.</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> and the effectiveness of internal control over financial reporting of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MacroGenics, Inc</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">. included in its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tysons, Virginia&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 23, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>filingfeetableexhibit107.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i175692aff661422590ff9574600d7e62_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 107</font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Calculation of Filing Fee Tables</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form S-8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Security Type</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Security Class Title</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fee Calculation Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(3)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount Registered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(1)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Proposed Maximum Offering Price Per Share</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maximum Aggregate Offering Price</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fee Rate</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of Registration Fee</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.57pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock, $0.01 par value per share</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457(c) and 457(h)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,000,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(2)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(3)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8,640,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.00014760</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,275.26</font></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Offering Amounts</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8,640,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,275.26</font></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Fee Offsets</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8211;</font></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Fee Due</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,275.26</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:362.75pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this Registration Statement shall also cover any additional shares of the Registrant&#8217;s Common Stock (&#8220;Common Stock&#8221;) that become issuable under the MacroGenics, Inc. 2023 Equity Incentive Plan (the &#8220;2023 EIP&#8221;) by reason of any stock dividend, stock split, recapitalization or other similar transaction.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Represents shares of common stock that were added to the shares reserved for future issuance under the 2023 EIP upon approval of an amendment to the 2023 EIP at the Registrant&#8217;s 2024 Annual Meeting of Stockholders. </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The price per share and aggregate offering price are calculated on the basis of $4.32, the average of the high and low price of the Registrant&#8217;s Common Stock as reported on the Nasdaq Global Select Market on May 21, 2024.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  ! T   %3" (   #=HV*:    "7!(67,  )]Z
M   T(@'=C#6Z     DE$051XG&*DD2L  "!7241!5.W:6W(D26X%T%Z*]J#]
M+ZA7D?K@&%7#(I/Y"/<+P,\Q_,A,Z@I<((*$4?_< ( %_OV?_]U3Z4:!F?Y)
M/P  S.1. %IS)P# $NX$H#5W @ LX4X 6G,G , 2[@2@-7<" "SA3@!:<R<
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MNA/BO^FJ=RJ]/@#E^ (#K56Y$^*_YJHW*[U! .7X @.ME;@3XK_CJO<KO40
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M@-:NN1/BEX"OYPIR!GB'GW1 :Q?<"?%+P'=S*6D#O,;/.Z"UL7?"^WWQ2>
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MG\C#S9XT0:E-3KT"\><_Y'V/1V>IFN[5@2'$]^':0%[[3\7;W[P2L[O;HVR
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M$P  J,Z1L)\[ 0" TOPQ(<*=  ! :>Z$"'<"  "E.1(BW D  -3ECPDI[@0
M .IR)*2X$P  *,H?$X+<"0  %.5("'(G  !0D3\F9+D3  "HR)&0Y4X  * <
M?TR(<R<  %"..R'.G0  0"V.A K<"0  U.).J,"=  ! (8Z$(MP)   4XDXH
MPIT  $ ACH0BW D  %3ACPEUN!,  *C"D5"'.P$ @!+\,:$4=P(  "4X$DIQ
M)P  D.>/"=6X$P  R',G5.-.   @S)%0D#L! ( P=T)![@0  )(<"36Y$P
M2'(GU.1.   @QI%0ECL! ( 8=T)9[@0  &(<"66Y$P  R/#'A,K<"0  9#@2
M*G,G   0X(\)Q;D3   (<"<4YTX  & W1T)][@0  '9S)]3G3@  8"M'0@ON
M!   MG(GM.!.  !@'T="%^X$  #V<2=TX4X  & 31T(C[@0  #9Q)S3B3@
M8!-'0B/N!   =O#'A%[<"0  [.!.Z,6=  # <HZ$=MP)   LYTYHQYT  ,!:
MCH2.W D  *SE3NC(G0  P$*.A*;<"0  +.1.:,J=  # *HZ$OMP)  "LXD[H
MRYT  , JCH2^W D  "SACPFMN1,  ("O_@]O*TDXKYC[_     !)14Y$KD)@
!@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
